Other
Crswnp
0
Pipeline Programs↗
7
Active Trials↗
2
Companies Involved↗
CRSwNP is an early-stage landscape with 0 programs across 2 companies. The most active players are Sanofi, AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
9
clinical trials
Recruiting3 · 33%
Not yet recruiting2 · 22%
Active, not recruiting2 · 22%
Completed1 · 11%
Withdrawn1 · 11%
Clinical Trials
Trial Activity
9 trials
Identifying Predictors Of Response To Mepolizumab In CRSwNP
Recruiting·—·Phase 4·NCT05902325·36 enrolled
Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks
Active, not recruiting·—·Phase 4·NCT05598814·58 enrolled
International Severe CRSwNP Registry 2024-2028
Active, not recruiting·—·N/A·NCT06617754·3,000 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)